Feb 6
More than a decade ago, a group of pharma R&D heads gathered for an annual meeting focused on addressing common industry challenges. They had a running joke: With an average tenure of just three years, if they wanted to see each other at more than one of these gatherings, they’d better figure out how to extend their survival odds.
Read the full article featuring Janice Chang from Pharmaceutical Executive here.
Related Blog Posts
How To Lead A Moonshot Collaboration: Lessons From Over A Decade Of Competitors Working Together
When TransCelerate launched more than a decade ago, few expected a collaboration among direct competitors to last, let alone grow into a durable, trusted organization. The numbers were seemingly against us: Most consortia struggle to survive beyond two years, typically dissolving once their founding champions retire or member companies deprioritize their involvement. Read the full…
Digital Protocols Are At An Inflection Point: A Conversation With Novartis And TransCelerate Leaders
Interest in digital approaches to clinical protocols has grown steadily as sponsors, solution providers, sites, and regulators explore ways to make study planning and execution more efficient. Read the full article featuring Rob DiCicco from Clinical Leader here.
Scrip Asks… What Does 2026 Hold For Biopharma? Part 2: Competitive Dynamics – A Landscape Reshaped
Regulatory divergence across major markets is creating strategic complexity that compounds geographic competitive pressures. Read the full article featuring Allison Cuff Shimooka from Citeline here.